[JUPITER study about rosuvastatin and risk of cardiovascular disease. Unclear consequences for the guideline].
Lubsen
Jacobus
J
Klinische Epidemiologie, Vufflens-le-Château, Zwitserland. jlubsen@compuserve.com
D002097:C-Reactive Protein / Q000187:drug effects* / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000097:blood / Q000517:prevention & control*; D003362:Cost-Benefit Analysis; D005464:Fluorobenzenes / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000191:economics / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D011743:Pyrimidines / Q000191:economics / Q000627:therapeutic use*; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000191:economics / Q000627:therapeutic use*; D016896:Treatment Outcome; D014481:United States
D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium; D002097:C-Reactive Protein